Cassava Sciences (SAVA) Set to Announce Earnings on Thursday

Cassava Sciences (NASDAQ:SAVA) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.37) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Cassava Sciences (NASDAQ:SAVA) last issued its earnings results on Thursday, August 8th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.57. During the same period last year, the company earned ($0.63) earnings per share. On average, analysts expect Cassava Sciences to post $-6 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cassava Sciences Trading Down 7.4 %

Shares of SAVA opened at $23.93 on Wednesday. Cassava Sciences has a 12-month low of $8.79 and a 12-month high of $42.20. The firm has a market capitalization of $1.15 billion, a P/E ratio of -16.97 and a beta of -0.59. The firm has a 50-day moving average price of $27.82 and a 200 day moving average price of $22.92.

Wall Street Analyst Weigh In

A number of research firms recently commented on SAVA. HC Wainwright upgraded Cassava Sciences from a “neutral” rating to a “buy” rating and set a $116.00 price objective on the stock in a report on Tuesday, October 8th. Rodman & Renshaw reaffirmed a “buy” rating and set a $107.00 price objective on shares of Cassava Sciences in a research report on Thursday, August 8th.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.